Skip to main content

Nonprofit · EIN 76-0585072

THE NASPGHAN FOUNDATION

Tax-exempt · AMBLER, PA 19002

Financials

$1.8M$1.7M2023$2.3M$1.9M2024
Revenue Expenses · by fiscal year end
Financials of THE NASPGHAN FOUNDATION by year, from its e-filed returns
Year endedFormRevenueExpensesNet incomeTotal assetsLiabilitiesNet assets
December 31, 2024990$2,269,887$1,855,146$414,741$8,213,426$1,756,363$6,457,063
December 31, 2023990$1,825,546$1,721,379$104,167$7,458,927$1,785,821$5,673,106
Financial details: 990 for the year ended December 31, 2024

Revenue

Contributions, gifts and grants
$2,258,912
Membership dues
$114,419
Program service revenue
$0
Investment income
$10,975
Net gain from sales of assets
-$169,062
Other revenue
$0

Expenses

Grants and similar amounts paid
$1,111,093
Compensation of officers, directors and key employees
$50,000
Other salaries and wages
$103,138
Salaries, compensation and benefits (total)
$169,033
Professional fundraising fees
$0
Accounting fees
$19,160
Occupancy
$23,411
Travel
$14,909
Program services (functional)
$1,718,889
Management and general (functional)
$85,189
Fundraising (functional)
$51,068

Balance sheet and other

Total assets, start of year
$7,458,927
Total assets, end of year
$8,213,426
Total liabilities, end of year
$1,756,363
Net assets, end of year
$6,457,063
Publicly traded securities
$4,619,190
Net assets without donor restrictions
$3,389,221
Net assets with donor restrictions
$3,067,842
Gross receipts
$4,887,567
Employees
0
Volunteers
60
Year formed
1988
State of legal domicile
TX

From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.

Officers, directors and key employees

As listed on the 990 for the year ended December 31, 2024, highest compensation first.

NameTitleHours / weekCompensationFrom related orgsOther / benefits
MARGARET STALLINGSEXECUTIVE DIRECTOR
Officer
20$50,000$290,666$30,500
ANN SCHEIMANN MD MBAPRESIDENT
Trustee or director, Officer
2$0$0$0
MENNO VERHAE MDPAST PRESIDENT
Trustee or director, Officer
2$0$0$0
JEANIE HUANG MD MPHSECRETARY/TREASURER
Trustee or director, Officer
1$0$0$0
ROBERT DAHMSDIRECTOR
Trustee or director
1$0$0$0
PRAVEEN GODAY MDDIRECTOR
Trustee or director
1$0$0$0
BENJAMIN GOLD MD FAAP FACGDIRECTOR
Trustee or director
1$0$0$0
SANDRA CHIHYUN KIM MDDIRECTOR
Trustee or director
1$0$0$0
ROHIT KOHLI MBBS MSDIRECTOR
Trustee or director
1$0$0$0
JENIFER R LIGHTDALE MD MPHDIRECTOR
Trustee or director
1$0$0$0
CARA MACK MDDIRECTOR
Trustee or director
1$0$0$0
MERCEDES MARTINEZDIRECTOR
Trustee or director
1$0$0$0
DEDRICK MOULTON MDDIRECTOR
Trustee or director
1$0$0$0
KAREN MURRAY MDDIRECTOR
Trustee or director
1$0$0$0
MARIA M OLIVA-HEMKER MDDIRECTOR
Trustee or director
1$0$0$0
3 more people on this return
NameTitleHours / weekCompensation
JOEL ROSH MDDIRECTOR
Trustee or director
1$0
MANU SOOD MDDIRECTOR
Trustee or director
1$0
JUSTINE TURNER MBBSDIRECTOR
Trustee or director
1$0
990 for the year ended December 31, 2023: 11 people
NameTitleHours / weekCompensationFrom related orgsOther / benefits
MARGARET STALLINGSEXECUTIVE DIRECTOR
Officer
20$50,000$167,072$6,096
MENNO VERHAVE MDPRESIDENT
Trustee or director, Officer
2$0$0$0
ANN SCHEIMANN MD MBAPRESIDENT
Trustee or director, Officer
2$0$0$0
PRAVEEN GODAY MDDIRECTOR
Trustee or director
1$0$0$0
BENJAMIN GOLD MD FAAP FACGDIRECTOR
Trustee or director
1$0$0$0
JEANIE HUANG MD MPHDIRECTOR
Trustee or director
1$0$0$0
KAREN MURRAY MDDIRECTOR
Trustee or director
1$0$0$0
VICKY NG MDDIRECTOR
Trustee or director
1$0$0$0
PATRICIA ROBUCK PHD MPHDIRECTOR
Trustee or director
1$0$0$0
JOEL ROSH MDDIRECTOR
Trustee or director
1$0$0$0
Robert DahmsDIRECTOR
Trustee or director
1$0$0$0

Address and contacts

Address (IRS master file)
714 N BETHLEHEM PIKE STE 300, AMBLER, PA 19002-2655
In care of
% EXECUTIVE DIRECTOR
Principal officer (990 for 2024)
CELENA T NUQUAY, 714 N BETHLEHEM PIKE 300, AMBLER, PA 19002
Signed the 990
CELENA T NUQUAY, EXECUTIVE DIRECTOR
Phone
(215) 641-9800
Return prepared by
MCKONLY & ASBURY LLP

Mission

THE NASPGHAN FOUNDATION FUNDS AND SUPPORTS THE RESEARCH AND EDUCATION MISSION OF NASPGHAN IN ORDER TO ENHANCE THE HEALTH AND WELL-BEING OF CHILDREN WITH GASTROINTESTINAL, LIVER, PANCREAS AND NUTRITIONAL DISORDERS.

990 for the year ended December 31, 2024

Program accomplishments

  • GRANTS AND AWARDS:(1) NASPGHAN/NASPGHAN FOUNDATION GEORGE FERRY YOUNG INVESTIGATOR DEVELOPMENT AWARD: - THIS TWO-YEAR GRANT IS AVAILABLE TO JUNIOR FACULTY TO SUPPORT RESEARCH ACTIVITIES THAT HAVE THE POTENTIAL FOR EVOLUTION TO AN INDEPENDENT RESEARCH CAREER IN PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY OR NUTRITION. MONIES ARE AWARDED IN SUPPORT OF A MERITORIOUS RESEARCH PROJECT IN THE CLINICAL OR BASIC SCIENCES TO STUDY THE DISEASES OF THE GASTROINTESTINAL TRACT, LIVER OR PANCREASE AND NUTRITIONAL DISORDERS IN CHILDREN.(2) NASPGHAN FOUNDATION/NESTLE NUTRITION RESEARCH YOUNG INVESTIGATOR DEVELOPMENT AWARD:- THIS TWO-YEAR GRANT IS AVAILABLE TO JUNIOR FACULTY TO SUPPORT RESEARCH ACTIVITIES THAT HAVE THE POTENTIAL FOR EVOLUTION TO AN INDEPENDENT RESEARCH CAREER IN PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY OR NUTRITION. THIS GRANT, GENEROUSLY SUPPORTED BY MEAD JOHNSON, IS AWARDED TO SUPPORT MERITORIOUS BASIC OR CLINICAL RESEARCH PROJECT RELATING TO NUTRITION IN INFANCY, CHILDHOOD OR ADOLESCENCE.(3) NASPGHAN FOUNDATION/TAKEDA PHARMACEUTICALS NORTH AMERICA INC RESEARCH INNOVATION AWARD:- THIS GRANT IS OFFERED IN ODD NUMBERED YEARS. THIS GRANT WILL PROVIDE $75,000 ANNUALLY FOR TWO YEARS (TOTAL $150,000) FOR INNOVATIVE, HIGH-IMPACT RESEARCH IN PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY AND NUTRITION. THE INTENT OF THIS RESEARCH AWARD IS TO STIMULATE SCIENTIFIC INQUIRY IN AN AREA THAT IS EXCEPTIONALLY INNOVATIVE AND HAS THE POTENTIAL TO IMPACT THE FIELD IN A HIGHLY NOVEL MANNER. APPLICANTS AT ANY CAREER LEVEL MAY APPLY.(4) NASPGHAN FOUNDATION/ASTRAZENECA RESEARCH IN PEPTIC ULCER DISEASES:- THIS GRANT WILL PROVIDE $75,000 ANNUALLY FOR TWO YEARS (TOTAL $150,000) FOR STUDIES FOCUSED ON THE EPIDEMIOLOGY, PATHOGENESIS, NATURAL HISTORY, GENETICS, DIAGNOSIS AND MANAGEMENT OF PEPTIC DISORDERS AND OTHER DISEASES OF THE UPPER GASTROINTESTINAL TRACT IN CHILDREN. DISEASES THAT ARE RELEVANT TO THIS ANNOUNCEMENT INCLUDE, BUT ARE NOT LIMITED TO GASTROESOPHAGEAL REFLUX, REFLUX ESOPHAGITIS, EOSINOPHILIC (ALLERGIC) ESOPHAGITIS, MOTILITY DISORDERS OF THE UPPER GASTROINTESTINAL TRACT, HELICOBACTER PYLORI INFECTION WITH OR WITHOUT ULCERATION, NON-ULCER DYSPEPSIA, AND NON-BACTERIAL ULCER DISEASES. APPLICANTS AT ANY CAREER LEVEL MAY APPLY.(5) NASPGHAN FOUNDATION MID-LEVEL CAREER DEVELOPMENT AWARD:THIS MID-LEVEL CAREER DEVELOPMENT AWARD IS FOR NASPGHAN MEMBERS PURSUING RESEARCH IN PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY AND NUTRITION AND ARE AT A MID-LEVEL IN THEIR CAREER. MID-LEVEL IS DEFINED AS A FACULTY MEMBER WHO HAS HELD A FACULTY APPOINTMENT FOR AT LEAST 6 YEARS AT THE TIME OF THE APPLICATION, BUT HAS NOT YET REACHED PROFESSOR LEVEL. THIS AWARD WILL PROVIDE UP TO $100,000 IN DIRECT FUNDING FOR 2 YEARS ($50,000 PER YEAR) FOR THE ADVANCEMENT OF RESEARCH CAREERS FOR APPLICANTS WITH SIGNIFICANT PROMISE IN THEIR MID-YEARS AS FACULTY. THE PROPOSAL MUST INCLUDE A FOCUSED AREA OF RESEARCH THAT WILL DIRECTLY ENHANCE THE APPLICANT'S ABILITY TO ACHIEVE FURTHER NATIONAL PEER-REVIEWED RESEARCH FUNDING AND RESULT IN SIGNIFICANT IMPACT ON GASTROINTESTINAL, NUTRITION AND LIVER HEALTH IN CHILDREN. BASIC, CLINICAL, TRANSLATIONAL, EPIDEMIOLOGIC, DISSEMINATION AND IMPLEMENTATION RESEARCH ARE ALL ENCOURAGED. THIS AWARD IS TO FOSTER EITHER A NEW AREA OF ENQUIRY OR TO PROVIDE PILOT DATA IN AN ONGOING AREA OF RESEARCH WITH SUBSTANTIAL POTENTIAL FOR NEW FUNDING.[6] NASPGHAN FOUNDATION/APGNN SUSAN MOYER NURSING RESEARCH GRANT:THIS ONE-YEAR GRANT IS AVAILABLE TO PEDIATRIC GASTROENTEROLOGY, NUTRITION AND HEPATOLOGY NURSES TO SUPPORT RESEARCH ACTIVITIES THAT HAVE THE POTENTIAL TO ADVANCE NURSING CARE OF PATIENTS AND FAMILIES OF CHILDREN WITH GASTROINTESTINAL, HEPATOBILIARY, OR NUTRITIONAL DISORDERS. MONIES ARE AWARDED IN SUPPORT OF A MERITORIOUS RESEARCH PROJECTS TO STUDY THE NURSING CARE OFFAMILIES AND CHILDREN WITH PEDIATRIC GASTROINTESTINAL, HEPATOBILIARY, PANCREATIC OR NUTRITIONAL DISORDERS.[7]NASPGHAN FOUNDATION/ABBOTT NUTRITION ADVANCED FELLOWSHIP TRAINING IN PEDIATRIC NUTRITION:THE AWARD IS EXPECTED TO BEGIN ON JULY 1 OF EACH ACADEMIC TERM ALTHOUGH ALTERNATE START DATESWILL BE CONSIDERED TO ACCOMMODATE NON-TRADITIONAL ACADEMIC SCHEDULES. PEDIATRIC NUTRITION IS ONE OF THE FASTEST GROWING AREAS OF SCIENTIFIC AND CLINICAL IMPORTANCE TO CHILD AND POPULATIONHEALTH. TO ADDRESS THIS GROWING INTEREST AND TO ACCELERATE THE TRAINING OF PEDIATRIC EXPERTS, THE NASPGHAN FOUNDATION HAS PARTNERED WITH ABBOTT NUTRITION TO DEVELOP A PATHWAY FOR ADVANCED FELLOWSHIP TRAINING IN PEDIATRIC NUTRITION. THE NASPGHAN FOUNDATION/ABBOTT NUTRITION ADVANCED FELLOWSHIP IN NUTRITION WILL PROVIDE UP TO $75,000 IN DIRECT FUNDING TO SUPPORT ONE YEAR OF ADVANCED TRAINING IN PEDIATRIC NUTRITION FOR A NASPGHAN MEMBER. APPLICANTS ARE EXPECTED TO IDENTIFY A MENTOR AND A HOST NUTRITION RESEARCH PROGRAM PRIOR TO APPLICATION FOR FUNDING. THE FELLOWSHIP MUST INCLUDE A WELL-DEFINED CLINICALEXPERIENCE AS WELL AS A FOCUSED RESEARCH PROJECT. EXAMPLES OF AREAS FOR EMPHASIS INCLUDE BUT ARE NOT LIMITED TO: FETAL GROWTH AND NEONATAL NUTRITION, TYPICAL DEVELOPMENT OF FEEDING SKILLS/BEHAVIORS AND FEEDING DISORDERS; NUTRITIONAL ASPECTS OF EATING DISORDERS SUCH AS ANOREXIA NERVOSA AND BULIMIA; MALNUTRITION AND FAILURE TO THRIVE; NUTRITION EDUCATION; NUTRITION IN SPECIFIC SYSTEMIC DISEASES OR CLINICAL STATES SUCH AS CYSTIC FIBROSIS, LIVER DISEASE, INTESTINAL FAILURE, AND ORGAN TRANSPLANTATION; NUTRITION SUPPORT; COMMUNITY NUTRITION; NUTRITION EPIDEMIOLOGY; ENERGY HOMEOSTASIS; NUTRITION AND THE MICROBIOME; MICRONUTRIENT HOMEOSTASIS;NUTRIGENOMICS; OBESITY; BREAST MILK AND BREAST FEEDING; AND BASIC LABORATORY NUTRITIONAL SCIENCE. THE PRIMARY OBJECTIVE OF THE FELLOWSHIP IS TO CATALYZE AND INCREASE THE NUMBER OF HIGHLY-TRAINED, EXPERT NUTRITION CLINICIANS, EDUCATORS AND SCIENTISTS AMONG THE MEMBERSHIP OF NASPGHAN, AS A MEANS TO IMPROVE SERVICE TO OUR PATIENTS AND THE PUBLIC.[8] NASPGHAN FOUNDATION INNOVATIONS IN CLINICAL CARE GRANT:THE AIM OF THIS GRANT IS TO ENCOURAGE AND SUPPORT THE DEVELOPMENT OF INNOVATIVE APPROACHES TO OPTIMIZE THE QUALITY OF CARE AND HEALTH CARE DELIVERY TO CHILDREN WITH DIGESTIVE DISEASES BY THECLINICALLY FOCUSED PEDIATRIC GASTROENTEROLOGIST. THE FOUNDATION WILL AWARD UP TO TWO GRANTS,EACH RANGING FROM $2,000 TO $5,000 FOR A ONE-YEAR PERIOD. SELECTION CRITERIA INCLUDE POTENTIAL IMPACT OF THE PROJECT ON PATIENT CARE AND THE APPLICABILITY OF THE PROJECT TO THE GENERAL NASPGHAN COMMUNITY. CLINICALLY ORIENTED PHYSICIANS ARE STRONGLY ENCOURAGED TO APPLY.[9] NASPGHAN FOUNDATION/QOL RESEARCH AWARD FOR THE STUDY OF DISORDERS ASSOCIATED WITH CARBOHYDRATE MALABSORPTION:THIS AWARD WILL PROVIDE $75,000 ANNUALY FOR TWO YEARS (TOTAL $150,000) FOR STUDIES FOCUSED ON DISORDERS OF CARBOHYDRATE (CHO) MALDIGESTION/MALABSORPTION IN CHILDREN. RELEVANT CONDITIONSINCLUDE, BUT ARE NOT LIMITED TO LACTOSE INTOLERANCE, CONGENITAL SUCROSE-ISOMALTASE DEFICIENCY,DISEASES LEADING TO INTESTINAL EPITHELIAL CELL DYSFUNCTION, SIBO, OR INFLAMMATORY CONDITIONS AFFECTING CHO ABSORPTION. APPLICANTS AT ANY CAREER LEVEL MAY APPLY.[10] NASPGHAN FOUNDATION/CPNP NUTRITION RESEARCH GRANT:THIS ONE-YEAR GRANT IS AVAILABLE TO PEDIATRIC DIETITIANS TO SUPPORT RESEARCH ACTIVITIES THAT HAVE THE POTENTIAL TO ADVANCE THE NUTRITION CARE OF PATIENTS AND FAMILIES OF CHILDREN WITH NUTRITIONAL DISORDERS. THE NASPGHAN FOUNDATION WILL AWARD GRANTS RANGING FROM $500 TO $5,000 FOR ONE YEAR.
    Expenses $1,171,096 · grants $1,111,093
  • EDUCATIONAL CAMPAIGNS:THE FOUNDATION SUPPORTS THE EDUCATIONAL MISSION OF NASPGHAN THROUGH A DIVERSE PORTFOLIO OF PROFESSIONAL AND PUBLIC EDUCATION INITIATIVES. TOPIC AREAS ARE REFLUX AND GERO, INFLAMMATORY BOWEL DISEASE, CELIAC DISEASE AND GLUTEN-RELATED DISORDERS, CONSTIPATION, EOSINOPHILIC ESOPHAGITIS, NUTRITION, ENDOSCOPY, AND NONALCOHOLIC FATTY LIVER DISEASE IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS. THE FOUNDATION'S GOAL IS TO EDUCATE MEDICAL PROFESSIONALS AND THE PUBLIC, AND TO SUPPORT THE DEVELOPMENT OF NEW RESEARCH IN THESE AREAS. THE PRIMARY OBJECTIVES ARE TO IMPROVE THE QUALITY OF LIFE AND TO CHANGE PEDIATRIC AND ADULT HEALTH OUTCOMES BY EARLY DETECTION AND INTERVENTION. GIKIDS IS THE PATIENT OUTREACH AND EDUCATION EFFORT OF NASPGHAN. WITH GIKIDS, ASPGHAN AND THE FOUNDATION ARE WORKING TO REACH OUT IRECTLY TO AMILIES,KIDS AND TEENS WHO LIVE WITH DIGESTIVE CONDTIONS TO PROVIDE THEM WITH THE INFORMATION THEY NEED TO:-UNDERSTAND AND IMPROVE THEIR DIGESTIVE HEALTH-WORK WITH THEIR HEALTH CARE PROVIDERS-LIVE A MORE INDEPENDENT LIFE-UNDERSTAND WHAT WORKS IN PLAIN LANGUAGE"A PRACTICAL APPROACH TO NUTRITIONAL MANAGEMENT OF CHILDREN WITH CHOLESTATIC LIVER DISEASES:TIPS FOR PATIENTS AND CAREGIVERS" WEBINAR AND ON DEMAND PROGRAM CHILDREN WITH CHOLESTATIC LIVER DISEASES HAVE UNIQUE NUTRITIONAL REQUIREMENTS.OBJECTIVES:1.OVERVIEW OF THE CLINICAL PRESENTATION AND LONG-TERM IMPLICATIONS OF MALNUTRITION AND FAT-SOLUBLE VITAMIN DEFICIENCIES IN CHILDRENWITH CHOLESTATIC LIVER DISORDERS.2.REVIEW CURRENT AVAILABLE FORMULATION AND PRACTICAL TIPS FOR THE CARE PROVIDER.3.REVIEW THE CURRENTLY AVAILABLE VITAMIN SUPPLEMENTS, FORMULATIONS AND DISCUSSION.4.DISCUSS LACK OF INSURANCE COVER FOR MEDICAL FOOD, VITAMINS AND FINANCIAL BURDEN TO THE FAMILIES. HEPATITIS C SLIDE SET AND GRAND ROUNDS HCV INFECTION IS CHILDREN IS FREQUENTLY UNRECOGNIZED. RECENTLY PROPOSED UNIVERSAL TESTING STRATEGIES DURING PREGNANCY NEED TO BEIMPLEMENTED. ALTHOUGH LIVER DISEASE IS GENERALLY MILD IN CHILDREN, CHRONIC HEPATITIS AND CIRRHOSIS OCCURS. DIRECT ACTIVE ANTIVIRALS ARE VERY EFFICACIOUS AND SAFE. THEREFORE, ALL HCV INFECTED CHILDREN> 3 YEARS OF AGE SHOULD BE CONSIDERED FOR TREATMENT. PUBLIC AND PROFESSIONAL EDUCATION IS CRITICALLY IMPORTANT TO INCREASE HCV AWARENESS. THE FOUNDATION DEVELOPED A SLIDE DECK AND GRAND ROUNDS PROGRAM TO INCREASE AWARENESS REGARDING TESTING ANDMANAGEMENT OF HCV. "NUTRITION AND LIVER DISEASE IN PEROXISOMAL BIOGENESIS DISORDERS: DIAGNOSIS AND MANAGEMENT" NASPGHAN NUTRITION UNIVERSITY (N2U) THIS COURSE IS DESIGNED TO PROVIDE SPECIALIZED NUTRITION EDUCATION IN AREAS ASSOCIATED WITH THE PRACTICE OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION TO 3RD YEAR FELLOWS, JUNIOR FACULTY AND DIETITIANS. IT TARGETS TWO GROUPS: CANDIDATES WHO RECEIVED MINIMAL NUTRITION EDUCATION DURING THEIR FELLOWSHIP OR WHOM PLAN TO PURSUE PEDIATRIC NUTRITION AS THEIR CAREER FOCUS.TEACHING AND TOMORROW UNDERREPRESENTED IN MEDICINE (URIM) PROGRAM THE PEDIATRIC GI TEACHING AND TOMORROW PROGRAM OF NASPGHAN STRIVES TO ATTRACT THE BRIGHTEST RESIDENTS TO SUBSPECIALTY TRAINING IN PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY AND NUTRITION. DUE TO THE EXCELLENT INTEREST IN THIS INNOVATIVE NASPGHAN PROGRAM, WE HAVE SEEN CONTINUAL GROWTH IN THE INTEREST AND APPLICATIONS TO GI TRAINING PROGRAMS THROUGH THE YEARS. THIS PROGRAM HAS BEEN RECENTLY EXPANDED TO PROVIDE SCHOLARSHIPS TO INTERESTED 1ST AND 2ND YEAR PEDIATRIC RESIDENTS AND 4TH YEAR MEDICAL STUDENTS WHO SELF-IDENTIFY AS UNDERREPRESENTED IN MEDICINE (URIM). IN ADDITIONTO NETWORKING WITH OTHER PARTICIPANTS WHILE ATTENDING THE PROGRAM'S SCHEDULED SESSIONS,THE URIM PROGRAM ATTENDEES ARE MATCHED UP WITH A NASPGHAN FELLOW AND/OR ATTENDING PHYSICIAN (A TEACHING AND TOMORROW PROGRAM ALUMNUS) WHO SERVES AS A POINT OF CONTACT AND AMBASSADOR TO THE ANNUAL MEETING. URIM NASPGHAN/NASPGHAN FOUNDATION MEDICAL STUDENT MENTORED SUMMER RESEARCH PROGRAM THE URIM NASPGHAN/NASPGHAN FOUNDATION MEDICAL STUDENT MENTORED SUMMER RESEARCH PROGRAM TAKES PLACE AT MULTIPLE SITES THROUGHOUTTHE U.S. AND CANADA AND PROVIDES MEDICAL STUDENTS WHO SELF-IDENTIFY AS URIM WITH A 10-WEEK RESEARCH EXPERIENCE UNDER THE MENTORSHIP OF BASIC OR CLINICAL SCIENTISTS WITH A RESEARCH FOCUSIN PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY, OR NUTRITION. CANDIDATES FOR THESE SCHOLARSHIPS MUST HAVE COMPLETED AT MINIMUM THEIR FIRST YEAR OF MEDICAL TRAINING AND BE IN GOOD STANDING ATACCREDITED MEDICAL SCHOOLS IN THE U.S. AND CANADA. REFERENCE IS GIVEN TO STUDENTS WHO ARE SEEKING A RESEARCH EXPERIENCE PREFERENCE IS GIVEN TO STUDENTS WHO ARE SEEKING A RESEARCH EXPERIENCE BETWEEN THE FIRST AND SECOND YEARS OF MEDICAL SCHOOL, THOUGH APPLICATIONS FROM ALL CURRENTLY ENROLLED STUDENTS ARE CONSIDERED. THESE STUDENTS ARE ALSO INVITED TO ATTEND THE ANNUAL MEETING, PRESENT A POSTER OF THEIR PROJECT AND PARTICIPATE IN THE TEACHING AND TOMORROW PROGRAM. EDUCATION THE FOUNDATION SUPPORTS THE EDUCATIONAL MISSION OF NASPGHAN THROUGH A DIVERSE PORTFOLIO OF PROFESSIONAL AND PUBLIC EDUCATION INITIATIVES. THE FOUNDATION'S GOAL IS TO EDUCATE MEDICAL PROFESSIONALS AND THE PUBLIC, AND TO SUPPORT THE DEVELOPMENT OF NEW KNOWLEDGE THROUGH RESEARCH. THE PRIMARY OBJECTIVES ARE TO IMPROVE THE QUALITY OF LIFE AND TO IMPROVE HEALTH OUTCOMES THROUGH EDUCATION, EARLY DETECTION AND EVIDENCE-BASED CARE.
    Expenses $547,793
  • WEBINARS AND ON-DEMAND EDUCATIONAL MODULES EGIDS: BEYOND THE ESOPHAGUS. EGIDS ARE A COLLECTION OF CHRONIC INFLAMMATORY DISEASES INCLUDING EOSINOPHILIC ESOPHAGITIS (EOE), EOSINOPHILIC GASTRITIS (EG) EOSINOPHILIC GASTROENTERITIS(EGE), AND EOSINOPHILIC COLITIS (EC). AMONG THE EGIDS, EOE HAS BECOME AN INCREASINGLY RECOGNIZED AND STUDIED CONDITION. VALIDATED METRICS HAVE BEEN ESTABLISHED TO QUANTIFY QUALITY OF LIFE, SYMPTOMS, HISTOLOGIC AND ENDOSCOPIC FINDINGS. IN ADDITION, THERE ARE WELL-ESTABLISHED, EFFECTIVETREATMENTS. THE SAME CANNOT BE SAID FOR EG, EGE, OR EC, WHICH LACKS WELL ESTABLISHED HISTOLOGIC CRITERIA FOR DIAGNOSIS, AND HAS A MORE UNCLEAR NATURAL HISTORY, NOR WELL-ESTABLISHED TREATMENTS. EGIDS: BEYOND THE ESOPHAGUS BRINGS TO LIGHT THE LATEST ON NON-EOE EGID, INCLUDING THE SIGNS AND SYMPTOMS; THE CRITERIA TO MAKE A DIAGNOSIS; WHAT OPTIONS EXIST FOR THERAPY,AND THE POTENTIAL MECHANISMS OF DISEASE. PRACTICAL TIPS IN THE NUTRITIONAL MANAGEMENT OF CHILDREN WITH CHOLESTATIC LIVER DISORDERS: A WEBINAR FOR PATIENTS, FAMILIES AND CAREGIVERS.THIS WEBINAR EXPLORES PRACTICAL APPROACHES TO THE NUTRITIONAL MANAGEMENT OF CHILDREN WITH CHOLESTATIC LIVER DISEASES, WITH SPECIAL TIPS FOR PATIENTS AND CAREGIVERS. PARTICIPANTS LEARN THECLINICAL PRESENTATION AND LONG-TERM IMPLICATIONS OF MALNUTRITION AND FAT-SOLUBLE VITAMIN DEFICIENCIES IN CHILDREN WITH CHOLESTATIC LIVER DISORDERS, BECOME ACQUAINTED WITH DIFFERENCES AMONG THE CURRENTLY AVAILABLE FORMULATION TO SUPPORT NUTRITION IN CHOLESTATIC BABIES, AND THE CURRENTLY AVAILABLE VITAMIN SUPPLEMENTS AND FORMULATIONS. THE LACK OF INSURANCE COVERAGE FORMEDICAL FOOD AND VITAMINS IS ALSO DISCUSSED.
  • CHILDREN WITH CHOLESTATIC LIVER DISEASE : DIAGNOSTICS, MEDICAL MANAGEMENT OF CHRONIC PANCREATITIS IN CHILDREN:MAXIMIZING TREATMENT AND IMPROVING OUTCOMES, REMOVING DIETING FROM DIET THERAPIES IN PEDIATRIC GI, THE WHAT, HOW AND IFS OF OPTIMIZING EARLY CHILDHOOD GROWTH AND LONG-TERM OUTCOMES, CHILDREN WITH CHOLESTATIC LIVER DISEASE: PRURITIS MANAGEMENT, NASPGHAN FELLOWS TOOLBOX WEBSITE, BOWEL SOUNDS EPISODES ON EARLY NUTRITION. CHOLESTATIC JAUNDICE IS A RARE PRESENTATION OF VARIOUS HEPATOBILIARY, METABOLIC, AND GENETIC DISORDERS . CHOLESTASIS TYPICALLY PRESENTS IN THENEONATAL/ INFANTILE PERIOD BUT CAN ALSO PRESENT LATE IN OLDER CHILDREN OR EVEN ADULTS . EARLY DIAGNOSIS AND APPROPRIATE MANAGEMENT OF THE UNDERLYING CONDITION ARE OF PARAMOUNT IMPORTANCE FOR OPTIMAL PROGNOSIS . DIAGNOSIS OF CHOLESTASIS NEEDS AN ARRAY OF INVESTIGATIONS INCLUDING BLOOD TESTS, IMAGING, GENETIC TESTING, AND INVASIVE PROCEDURES LIKE LIVER BIOPSY . LIVER BIOPSY IS ONE OF THE CENTRAL CRUCIAL INVESTIGATIONS DONE IN EVALUATING CHILDREN WITH CHOLESTASIS, HOWEVER, CAN BE ASSOCIATED WITH COMPLICATIONS INCLUDING BLEEDING . UNDERSTANDING WHEN TO USE A LIVER BIOPSY IN CHILDREN WITH CHOLESTASIS ALONG WITH ITS LIMITATIONS IS EXTREMELY IMPORTANT TO GAIN THE MAXIMUM BENEFIT OUT OF AN INVASIVE PROCEDURE. OVER THE LAST DECADE, THE GROWTH IN GENETIC TECHNIQUES AND THE IDENTIFICATION OF NEW GENES LEADING TO CHOLESTASIS IN CHILDREN HAVEEVOLVED SIGNIFICANTLY AND HAVE LED TO THE SHRINKING OF THE UNIDENTIFIED ETIOLOGIES. THIS WEBINAR ADDRESSES THE RAPIDLY EVOLVING FIELD OF GENETIC CHOLESTASIS AND WHEN TO PERFORM A LIVER BIOPSY,ITS UTILITY, AND LIMITATIONS. MEDICAL MANAGEMENT OF CHRONIC PANCREATITIS IN CHILDREN : MAXIMIZINGTREATMENT AND IMPROVING OUTCOMES CHRONIC PANCREATITIS (CP) IN CHILDREN IS ASSOCIATED WITH SIGNIFICANT MORBIDITY AND POOR QUALITY OF LIFE . THE INCIDENCE OF CP IN CHILDREN HAS RISEN OVER THE PAST FEW DECADES AND IS APPROACHING THAT SEEN IN THE ADULT POPULATION . CP IS AN INFLAMMATORY DISEASE RESULTING IN IRREVERSIBLE CHANGES IN THE PANCREAS INCLUDING ACINAR CELL LOSS, FIBROSIS, DUCTAL CHANGES, AND CALCIFICATIONS . PATIENTS WITH CP MAY SUFFER FROM ABDOMINAL PAIN AND COMPLICATIONS OF EXOCRINE PANCREATIC INSUFFICIENCY (EPI) AND DIABETES MELLITUS . MEDICAL MANAGEMENT OF CHRONIC PANCREATITIS IN CHILDREN : MAXIMIZING TREATMENT AND IMPROVINGOUTCOMES BRINGS TOGETHER LEADING EXPERTS TO DISCUSS HOW TO ENSURE THAT CHILDHOOD CP IS RECOGNIZED EARLY AND ITS SEQUALAE TREATED PROMPTLY . REMOVING DIETING FROM DIET THERAPIES IN PEDIATRIC GI OBESITY WAS DECLARED AN EPIDEMIC BY THE CDC IN THE 1990S, YET SIGNIFICANT AND SUSTAINED WEIGHT LOSS CONTINUES TO BE PROBLEMATIC FOR AMERICANS AS A POPULATION . CRITICAL FACTORS ARE OFTEN OVERLOOKED WHEN ADDRESSING OBESITY SUCH AS RACIAL DISCRIMINATION, DISABILITY STATUS, AND ENVIRONMENTAL FACTORS. IN CONJUNCTION, "WEIGHT STIGMA", OR BIAS THAT DEVALUES PEOPLE WITH LARGER BODIES, CAN CAUSE INCREASED MORBIDITY AND MORTALITY, INDEPENDENT OF BMI. AS A RESPONSE, A MOVEMENT IS TAKING PLACE, KNOWN BY SEVERAL NAMES INCLUDING "ANTI-DIET OR "INTUITIVE EATING". THIS IS AN INCLUSIVE MOVEMENT THAT RECOGNIZES ONE'S SIZE AS PART OF HIS OR HER IDENTITY AS MUCH AS RACE, NATIONAL ORIGIN, AND SEXUALITY. IT CONSIDERS SOCIAL, ECONOMIC, AND PHYSICAL BARRIERS TO OBESITY, RATHER THAN ASSUMING LACK OF WILLPOWER OR EDUCATION ARE THECAUSE . IT'S ABOUT RECOGNIZING "DIET CULTURE AND DISMANTLING THE ANTI-FAT AND PRO-THIN MESSAGES THAT INFILTRATE SOCIETY . THIS INFORMATIVE AND INTERACTIVE WEBINAR HELPS HEALTHCARE PROVIDERSRECOGNIZE WEIGHT STIGMA AND PROMOTE A POSITIVE RELATIONSHIP WITH FOOD, PARTICULARLY IN PATIENTS WITH GI-RELATED HEALTH CONDITIONS AND THOSE FOLLOWING THERAPEUTIC DIETS. THE WHAT, HOW AND IFS OF OPTIMIZING EARLY CHILDHOOD GROWTH AND LONG-TERM OUTCOMES : PART ONE UNDERSTANDING NORMAL GROWTH AND DEVELOPMENT IS CRITICALLY ESSENTIAL FOR QUICK RECOGNITION AND INTERVENTION FOR DEVIATIONS IN CHILDHOOD GROWTH AND NUTRIENT INTAKE PRACTICES ASSOCIATED WITH INCREASED RISK FOR DISEASE AND POOR LONG-TERM HEALTH . NUTRIENT AND NON-NUTRIENT FACTORS INFLUENCE HEALTH OUTCOMES THROUGHOUT THE LIFECYCLE . THIS WEBINAR AND PODCAST SERIES, THE WHAT, HOW AND IFS OF OPTIMIZING EARLY CHILDHOOD GROWTH AND LONG-TERM OUTCOMES DISCUSSES HOW TO IMPLEMENT NUTRIENT AND NON-NUTRIENT FACTORS THAT OPTIMIZE LONG-TERM HEALTH, RECOGNIZE CHILDHOOD GROWTH AND NUTRIENT INTAKE PATTERNS ASSOCIATED WITH DISEASE, CHILDHOOD MICROBIOME AND LONG-TERM RISK FOR DISEASE, AND EARLY DIAGNOSIS AND MANAGEMENT STRATEGIES FOR CHILDHOOD FEEDING DISORDERS. THE WHAT, HOW AND IFS OF OPTIMIZING EARLY CHILDHOOD GROWTH AND LONG-TERM OUTCOMES : PART TWO UNDERSTANDING NORMAL CHILDHOOD GROWTH IS ESSENTIAL FOR QUICK RECOGNITION AND INTERVENTION FOR DEVIATIONS IN GROWTH AND NUTRIENT INTAKE ASSOCIATED WITH LONG-TERM RISK FOR DISEASE AND POOR HEALTH . THEREFORE, THE 'WHAT, HOW, AND IFS OF OPTIMIZING CHILDHOOD GROWTH AND LONG-TERM OUTCOMES' WEBINAR SERIES ADDRESSES THE KNOWLEDGE AND PRACTICE GAPS ABOUT NUTRIENT AND NON-NUTRIENT FACTORS ESSENTIAL FOR OPTIMIZING LONG-TERM HEALTH OUTCOMES . THE FIRST WEBINAR ADDRESSES THE EARLY LIFE NUTRITIONAL FACTORS THATPROMOTE HEALTHY GROWTH, THE DEVELOPMENT OF A MICROBIOME ASSOCIATED WITH OPTIMIZED LONG-TERM HEALTH, AND THE RECOGNITION OF EARLY CHILDHOOD GROWTH PATTERNS RELATED TO LONG-TERM RISK FOR OVERWEIGHT AND OBESITY . THIS PART TWO WEBINAR FOCUSES ON A NUTRITIONAL ASSESSMENT APPROACH THAT QUICKLY RECOGNIZES DISEASE, NUTRITIONAL MANAGEMENT OF CHILDHOOD FEEDINGDISORDERS, AND PRINCIPLES AND STRATEGIES FOR WEANING CHILDREN FROM DEPENDENCE ON TUBE FEEDS .CHILDREN WITH CHOLESTATIC LIVER DISEASE : PRURITIS MANAGEMENT PRURITUS IS A COMMON COMPLICATION OF CHOLESTATIC LIVER DISEASE THAT CAN SIGNIFICANTLY IMPAIR QUALITY OF LIFE. INTRACTABLE PRURITUS IS AN INDICATION FOR LIVER TRANSPLANT REGARDLESS OF PELD/ MELD SCORE.THE PATHOPHYSIOLOGY OF PRURITUS IS COMPLEX. SEVERAL MEDICATIONS SERVE AS STANDARDS FOR TREATMENT AND RECENT ADVANCES IN QUANTIFICATION HAS ALLOWED FOR RIGOROUS AND CONTROLLED STUDY OF NEW MEDICATIONS. IN CERTAIN CIRCUMSTANCES, LIVER TRANSPLANT CAN BE AVOIDED OR DELAYED WITH SURGICAL BILIARY INTERVENTION . NASPGHAN FELLOWS TOOLBOX WEBSITE THE NASPGHAN TOOLBOX WEBSITE IS DESIGNED TO DELIVER PEDIATRIC GASTROENTEROLOGY INFORMATION TO CARE PROVIDERS IN A FORMAT THAT IS USER FRIENDLY . THE TOOLBOX PROVIDES EASY ACCESS TO CLINICAL GUIDELINES FORPEDIATRIC GASTROENTEROLOGISTS AND TRAINEES AND IS NOW AVAILABLE AS A DISTINCT WEBSITE LINKED FROM THE NASPGHAN WEBSITE . FEATURES OF THE TOOLBOX INCLUDE ALGORITHMS TO NAVIGATE CLINICAL GUIDELINES FOR VARIOUS DISEASES; HIGH QUALITY IMAGES OF GI PATHOLOGY; HELPFUL TABLES ON MANAGING NUTRITIONAL NEEDS; SCORES AND CALCULATORS TO ASSIST IN CALCULATING IMPORTANT PEDIATRIC GI SCORES; AND A CONVENIENT SEARCH FEATURE . BOWEL SOUNDS EPISODES ON EARLY NUTRITION BOWEL SOUNDS IS A PODCAST ON ALL THINGS RELATED TO PEDIATRIC GASTROENTEROLOGY, HEPATOLOGY, AND NUTRITION . EPISODES FEATURE INTERVIEWS WITH EXPERTS OFFERING CLINICAL AND ACADEMIC PEARLS ANDCAREER ADVICE WITH SOMETHING FOR EVERYONE REGARDLESS OF CAREER STAGE OR DISCIPLINE. NEW EPISODES ARE RELEASED EVERY OTHER MONDAY. TWO BOWEL SOUNDS EPISODES WHICH FOCUS ON EARLY CHILDHOOD NUTRITION INCLUDE : EARLY LIFE NUTRITION AND IMPACT ON CHILDHOOD DEVELOPMENT AND THE ROLE OF THE MICROBIOME IN HEALTHY INFANT AND EARLY CHILDHOOD NUTRITION.

What it must file and when

IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.

Tax yearYear endedDueIRS public records
2025December 31, 2025May 15, 2026Not on file
2024December 31, 2024May 15, 2025990 on file
2023December 31, 2023May 15, 2024990 on file

IRS record

EIN
76-0585072
Tax-exempt status
501(c)(3): Charitable, religious, educational or scientific organization
Foundation status
Publicly supported organization (170(b)(1)(A)(vi))
Donations deductible (Pub 78)
Public charity, 50% deduction limit
Exempt since
1999
Accounting year ends
December
Files
Form 990 or 990-EZ
Category (NTEE)
Medical research (H12)
Assets (IRS master file)
$8,213,426
Income (IRS master file)
$4,887,567

Filing history

FormYear endedRevenueExpensesAssetsReturn
990December 2024$2,269,887$1,855,146$8,213,426XML
990December 2023$1,825,546$1,721,379$7,458,927XML
990December 2022$1,995,391$1,511,688$6,677,645IRS
990December 2021–––IRS
990December 2020–––IRS
990December 2019–––IRS
990December 2018–––IRS

990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 76-0585072).

Questions about THE NASPGHAN FOUNDATION

What is the EIN of THE NASPGHAN FOUNDATION?
The employer identification number (EIN) of THE NASPGHAN FOUNDATION is 76-0585072.
Is THE NASPGHAN FOUNDATION tax-exempt?
Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 1999.
Are donations to THE NASPGHAN FOUNDATION tax-deductible?
Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
Which annual return does THE NASPGHAN FOUNDATION file?
Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
When is the next return of THE NASPGHAN FOUNDATION due?
The return for tax year 2025 (the year ending December 31, 2025) is due May 15, 2026. Form 8868 extends it by six months; the 990-N cannot be extended.
When did THE NASPGHAN FOUNDATION last file with the IRS?
The latest return in the IRS public files is the 990 for the year ended December 2024.
Who is the principal officer of THE NASPGHAN FOUNDATION?
The 990 for the year ended December 31, 2024 names CELENA T NUQUAY.
Who are the officers and directors of THE NASPGHAN FOUNDATION?
The 990 for the year ended December 31, 2024 lists 18 people; 1 received compensation from the organization, the highest $50,000 (MARGARET STALLINGS, EXECUTIVE DIRECTOR).
How much revenue does THE NASPGHAN FOUNDATION have?
On its 990 for the year ended December 31, 2024 it reported revenue of $2,269,887, expenses of $1,855,146 and total assets of $8,213,426 at year end.

Other nonprofits in AMBLER

All nonprofits in AMBLER · Pennsylvania · Medical research